Norman J. Lacayo, MD

Professional Education

Internship: UCSF Medical Center (1990) CA

Residency: UCSF Medical Center (1992) CA

Board Certification: Hematology/Oncology, American Board of Pediatrics (1996)

Fellowship: Stanford University Medical Center (1995) CA

Medical Education: UCSF School of Medicine (1989) CA

MD, U.C., San Francisco, Medicine (1989)

BA, U. C., Berkeley, Biochemistry (1985)

Honors & Awards

Molecular and Pharmacologic Correlates of Acute Myeloid Leukemia in Down Syndrome, NIH ROI subcontract from Wayne State University (01/09-04/16)

Banking Acute Leukemia Specimens at Lucile Packard Children’s Hospital: Hyundai Infrastructure Grant, Hyundai Foundation (10/11-09/12)

New Approaches in Pediatric Myeloid Leukemia, V Foundation (10/09-09/12)

Member, Alpha Omega Alpha (1990)

Administrative Appointments

Myeloid Steering Committee, Children's Oncology Group, 2007

Member, Cancer Center, 2007

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Hospital & Clinics patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group
Lacayo, N. J., Alonzo, T. A., Gayko, U., Rosen, D. B., Westfall, M., & Meshinchi, S. (2013). Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. BRITISH JOURNAL OF HAEMATOLOGY, 162(2), 250-262.

Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421
O'Brien, M. M., Cao, X., Pounds, S., Dahl, G. V., Raimondi, S. C., & Rubnitz, J. E. (2013). Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. LEUKEMIA, 27(3), 731-734.

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
Rosen, D. B., Harrington, K. H., Cordeiro, J. A., Leung, L. Y., Putta, S., & Walter, R. B. (2013). AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin. PLOS ONE, 8(1).

Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia
Gawad, C., Pepin, F., Carlton, V. Eh., Klinger, M., Logan, A. C., & Lacayo, N. (2012). Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. BLOOD, 120(22), 4407-4417.

Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML
Rosen, D. B., Cordeiro, J. A., Cohen, A., Lacayo, N., Hogge, D., & Cesano, A. (2012). Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. LEUKEMIA RESEARCH, 36(7), 900-904.

Circular RNAs Are the Predominant Transcript Isoform from Hundreds of Human Genes in Diverse Cell Types
Salzman, J., Gawad, C., Wang, P. L., Lacayo, N., & Brown, P. O. (2012). Circular RNAs Are the Predominant Transcript Isoform from Hundreds of Human Genes in Diverse Cell Types. PLOS ONE, 7(2).

Dorsolateral Midbrain MRI Abnormalities and Ocular Motor Deficits Following Cytarabine-Based Chemotherapy for Acute Myelogenous Leukemia
Doan, T., Lacayo, N., Fisher, P. G., & Liao, Y. J. (2011). Dorsolateral Midbrain MRI Abnormalities and Ocular Motor Deficits Following Cytarabine-Based Chemotherapy for Acute Myelogenous Leukemia. JOURNAL OF NEURO-OPHTHALMOLOGY, 31(1), 52-53.

A pilot study of an online cognitive rehabilitation program for executive function skills in children with cancer-related brain injury
Kesler, S. R., Lacayo, N. J., & Jo, B. (2011). A pilot study of an online cognitive rehabilitation program for executive function skills in children with cancer-related brain injury. BRAIN INJURY, 25(1), 101-112.

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Rubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., & Campana, D. (2010). Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. LANCET ONCOLOGY, 11(6), 543-552.

Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group
O'Brien, M. M., Lacayo, N. J., Lum, B. L., Kshirsagar, S., Buck, S., & Dahl, G. V. (2010). Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group. PEDIATRIC BLOOD & CANCER, 54(5), 694-702.

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
Pollard, J. A., Alonzo, T. A., Gerbing, R. B., Ho, P. A., Zeng, R., & Meshinchi, S. (2010). Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. BLOOD, 115(12), 2372-2379.

WT1 Expression at Diagnosis Does Not Predict Survival in Pediatric AML: A Report From the Children's Oncology Group
Noronha, S. A., Farrar, J. E., Alonzo, T. A., Gerbing, R. B., Lacayo, N. J., & Loeb, D. M. (2009). WT1 Expression at Diagnosis Does Not Predict Survival in Pediatric AML: A Report From the Children's Oncology Group. PEDIATRIC BLOOD & CANCER, 53(6), 1136-1139.

Speeding the Flow Toward Personalized Therapy in Childhood Acute Leukemia
Simonds, E. F., Davis, K. L., & Lacayo, N. J. (2009). Speeding the Flow Toward Personalized Therapy in Childhood Acute Leukemia. PEDIATRIC BLOOD & CANCER, 53(4), 525-526.

Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia
Schiffman, J. D., Wang, Y., McPherson, L. A., Welch, K., Zhang, N., & Ji, H. P. (2009). Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. CANCER GENETICS AND CYTOGENETICS, 193(1), 9-18.

Genomics of childhood leukemias: The virtue of complexity
Sikic, B. I., Tibshirani, R., & Lacayo, N. J. (2008). Genomics of childhood leukemias: The virtue of complexity. JOURNAL OF CLINICAL ONCOLOGY, 26(27), 4367-4368.

Tissue microarrays from bone marrow aspirates for high-throughput assessment of immunohistologic markers in pediatric acute leukemia
Hazard, F. K., Zhao, S., Schiffman, J. D., Lacayo, N. J., Dahl, G. V., & Natkunam, Y. (2008). Tissue microarrays from bone marrow aspirates for high-throughput assessment of immunohistologic markers in pediatric acute leukemia. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 11(4), 283-290.

Acute leukemia in children
O'Brien, M. M., & Lacayo, N. J. (2008). Acute leukemia in children. DM DISEASE-A-MONTH, 54(4), 202-225.

The incidence and clinical significance of nucleophosmin mutations in childhood AML
Brown, P., McIntyre, E., Rau, R., Meshinchi, S., Lacayo, N., & Small, D. (2007). The incidence and clinical significance of nucleophosmin mutations in childhood AML. BLOOD, 110(3), 979-985.

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias
Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., & Sikic, B. I. (2007). Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. JOURNAL OF CLINICAL ONCOLOGY, 25(11), 1341-1349.

CpG island methylator phenotype and childhood leukemia
Lacayo, N. J., Di Martino, J. F., Wei, M. C., & Dahl, G. V. (2006). CpG island methylator phenotype and childhood leukemia. CLINICAL CANCER RESEARCH, 12(16), 4787-4789.

Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein
DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., & Dahl, G. (2006). Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. LEUKEMIA, 20(3), 426-432.

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421
Becton, D., Dahl, G. V., Ravindranath, Y., Chang, M. N., Behm, F. G., & Weinstein, H. (2006). Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. BLOOD, 107(4), 1315-1324.

Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421.
Lacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., & Dahl, G. V. (2005). Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421. BLOOD, 106(11), 667A-667A.

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes
Lacayo, N. J., Meshinchi, S., Kinnunen, P., Yu, R., Wang, Y., & Dahl, G. V. (2004). Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. BLOOD, 104(9), 2646-2654.

Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.
Lacayo, N. J., Duran, G. E., & Sikic, B. I. (2003). Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Journal of experimental therapeutics & oncology, 3(3), 127-135.

Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma
Chen, G. K., Lacayo, N. J., Duran, G. E., Wang, Y., Bangs, C. D., & Sikic, B. I. (2002). Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. GENES CHROMOSOMES & CANCER, 34(4), 372-383.

Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia
Lacayo, N. J., Lum, B. L., Becton, D. L., Weinstein, H., Ravindranath, Y., & Dahl, G. V. (2002). Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. LEUKEMIA, 16(5), 920-927.

Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia
Dahl, G. V., Lacayo, N. J., Brophy, N., Dunussi-Joannopoulos, K., Weinstein, H. J., & Arceci, R. J. (2000). Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 18(9), 1867-1875.

Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant p-glycoprotein with deleted Phe(335)
Chen, G. K., Lacayo, N. J., Duran, G. E., Cohen, D., & Sikic, B. I. (2000). Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant p-glycoprotein with deleted Phe(335). MOLECULAR PHARMACOLOGY, 57(4), 769-777.

Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins
Chen, G., Duran, G. E., Steger, K. A., Lacayo, N. J., Jaffrezou, J. P., & Sikic, B. I. (1997). Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. JOURNAL OF BIOLOGICAL CHEMISTRY, 272(9), 5974-5982.